The former President of Israel, Reuven Rivlin, with the first vaccinator in Phase B of the IIBR-100 vaccine of the Israel Institute for Biological Research, at the Barzilai Medical Center.
Vaccine description
Vaccine typeViral vector
Clinical data
Other namesBrilife
Routes of
ATC code
  • None

BriLife, also known as IIBR-100, is a replication-competent recombinant VSV viral vectored COVID-19 vaccine candidate.[1][2][3][4] It was developed by the Israel Institute for Biological Research (IIBR).[1][5][6] The IIBR partnered with the US-based NRx Pharmaceuticals to complete clinical trials and commercialize the vaccine.[7][8] A study conducted in hamsters suggested that one dose of the vaccine was safe and effective at protecting against COVID-19.[9][3]


  1. ^ a b Karpiński, Tomasz M.; Ożarowski, Marcin; Seremak-Mrozikiewicz, Agnieszka; Wolski, Hubert; Wlodkowic, Donald (1 January 2021). "The 2020 race towards SARS-CoV-2 specific vaccines". Theranostics. 11 (4): 1690–1702. doi:10.7150/thno.53691. ISSN 1838-7640. PMC 7778607. PMID 33408775.
  2. ^ Bezbaruah, Rajashri; Borah, Pobitra; Kakoti, Bibhuti Bhushan; Al-Shar’I, Nizar A.; Chandrasekaran, Balakumar; Jaradat, Da’san M. M.; Al-Zeer, Munir A.; Abu-Romman, Saeid (2021). "Developmental Landscape of Potential Vaccine Candidates Based on Viral Vector for Prophylaxis of COVID-19". Frontiers in Molecular Biosciences. 8: 96. doi:10.3389/fmolb.2021.635337. ISSN 2296-889X. PMC 8082173. PMID 33937326.
  3. ^ a b Pushparajah, Deborah; Jimenez, Salma; Wong, Shirley; Alattas, Hibah; Nafissi, Nafiseh; Slavcev, Roderick A. (1 March 2021). "Advances in gene-based vaccine platforms to address the COVID-19 pandemic". Advanced Drug Delivery Reviews. 170: 113–141. doi:10.1016/j.addr.2021.01.003. ISSN 0169-409X. PMC 7789827. PMID 33422546.
  4. ^ Venkadapathi, Jeyanthi; Govindarajan, Venkat Kumar; Sekaran, Saravanan; Venkatapathy, Santhi (9 June 2021). "A Minireview of the Promising Drugs and Vaccines in Pipeline for the Treatment of COVID-19 and Current Update on Clinical Trials". Frontiers in Molecular Biosciences. 8: 637378. doi:10.3389/fmolb.2021.637378. ISSN 2296-889X. PMC 8219860. PMID 34179072.
  5. ^ Clinical trial number NCT04608305 for "Phase I/II Randomized, Multi-Center, Placebo-Controlled, Dose-Escalation Study to Evaluate the Safety, Immunogenicity and Potential Efficacy of an rVSV-SARS-CoV-2-S Vaccine (IIBR-100) in Adults" at
  6. ^ Scarabel, Lucia; Guardascione, Michela; Dal Bo, Michele; Toffoli, Giuseppe (1 March 2021). "Pharmacological strategies to prevent SARS-CoV-2 infection and treat the early phases of COVID-19". International Journal of Infectious Diseases. 104: 441–451. doi:10.1016/j.ijid.2021.01.035. ISSN 1201-9712. PMC 7816887. PMID 33476760.
  7. ^ Rabinovitch, Ari; Williams, Dan (12 July 2021). Grebler, Dan (ed.). "Israel partners with NRx Pharmaceuticals to commercialize COVID vaccine". Reuters. Retrieved 10 November 2021.
  8. ^ "Israeli-produced vaccine shipped to Georgia for Phase II trial". i24 News. 15 August 2021. Retrieved 10 November 2021.
  9. ^ Yahalom-Ronen, Yfat; Tamir, Hadas; Melamed, Sharon; Politi, Boaz; Shifman, Ohad; Achdout, Hagit; Vitner, Einat B.; Israeli, Ofir; Milrot, Elad; Stein, Dana; Cohen-Gihon, Inbar (16 December 2020). Shlomi Lazar, Hila Gutman, Itai Glinert, Lilach Cherry, Yaron Vagima, Shirley Lazar, Shay Weiss, Amir Ben-Shmuel, Roy Avraham, Reut Puni, Edith Lupu, Elad Bar-David, Assa Sittner, Noam Erez, Ran Zichel, Emanuelle Mamroud, Ohad Mazor, Haim Levy, Orly Laskar, Shmuel Yitzhaki, Shmuel C. Shapira, Anat Zvi, Adi Beth-Din, Nir Paran & Tomer Israely. "A single dose of recombinant VSV-∆G-spike vaccine provides protection against SARS-CoV-2 challenge". Nature Communications. 11 (1): 6402. doi:10.1038/s41467-020-20228-7. ISSN 2041-1723. PMC 7745033. PMID 33328475.

External links

Media files used on this page

Translation to english arrow.svg
(c) Tkgd2007 at en.wikipedia, CC-BY-SA-3.0
This is a one-way "translation arrow" icon, drawn by myself in the style of, and modeled after :Image:Translation_arrow.svg. It is meant to more accurately illustrate the process of translating from one regional written language into english
Coronavirus. SARS-CoV-2.png
Author/Creator: Alexey Solodovnikov (Idea, Producer, CG, Editor), Valeria Arkhipova (Scientific Сonsultant), Licence: CC BY-SA 4.0
Scientifically accurate atomic model of the external structure of the Severe Acute Respiratory Syndrome CoronaVirus 2 (SARS-CoV-2), a strain (genetic variant) of the coronavirus that caused coronavirus disease (COVID-19), first identified in Wuhan, China, during December 2019

Each separate locus (amorphous blob) is an atom of:

cobalt: membrane
crimson: E protein
green: M protein
orange: glucose (glycan)
turquoise : S (spike) glycoprotein
SARS-CoV-2 (Wikimedia colors).svg
Author/Creator: Geraki, Licence: CC BY-SA 4.0
SARS-CoV-2 logo in Wikimedia colors
Scholia logo.svg
Author/Creator: Lars Willighagen, Licence: CC BY-SA 4.0
SVG remake of proposal for Scholia logo (File:Scholia logo.png by User:Theklan).
WHO Rod.svg
The rod of Asclepius as depicted in the WHO logo.
Author/Creator: User:FoeNyx © 2004 (artistic illustration), Licence: CC-BY-SA-3.0
VIH - HIV / SIDA - AIDS viruses.
Syringe with Green Fluid.jpg
Author/Creator: Andres Rueda, Licence: CC BY 2.0
The following is the author's description of the photograph quoted directly from the photograph's Flickr page.
"Just wanted to test something with my ink refiller syringe. Filled with a oral-b mouthwash to give the greenish-blueish Max Payne valkyr effect. "
SARS-CoV-2 (CDC-23312).png
This illustration, created at the Centers for Disease Control and Prevention (CDC), reveals ultrastructural morphology exhibited by the 2019 Novel Coronavirus (2019-nCoV). Note the spikes that adorn the outer surface of the virus, which impart the look of a corona surrounding the virion, when viewed electron microscopically. This virus was identified as the cause of an outbreak of respiratory illness first detected in Wuhan, China.